Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
B cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma (DLBCL) and Burkitt's lymphoma (BL) (B-UNC/BL/DLBCL) is a new category of tumors that have features resembling both DLBCL and BL. These tumors have large and medium sized cells with greater irregularity of nuclei and more prominent nucleoli than BL. Approximately 35% to 50% have C-MYC rearrangements, although half are non-immunoglobulin variants. We identified six cases of B-UNC/BL/DLBCL with low-level IGH amplification. Four patients died with a median survival of 7 months (range, 6-20). In conclusion, to our knowledge low-level IGH amplification has not been previously described and should be evaluated for in this patient population.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4041348 | PMC |
| http://dx.doi.org/10.1186/2050-7771-2-9 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Concentration and integrity index of circulating cell-free DNA as a biomarker in pediatric patients with B-ALL.
Cell Mol Biol (Noisy-le-grand)
September 2025
Doctorado en Genética Humana, Centro Universitario de Ciencias de la Salud. Universidad de Guadalajara, Jalisco, México.
The objective of this study was to evaluate the concentration and integrity index of circulating cell-free DNA (ccf-DNA) as biomarkers for the detection and monitoring of minimal residual disease (MRD) in pediatric patients with B-cell acute lymphoblastic leukemia (B-ALL). Comparison with a validated methodology for the quantification of monoclonal rearrangements of the IGH gene was made. Peripheral blood and bone marrow samples were collected from 10 pediatric patients with B-ALL at diagnosis, remission, and maintenance phases.
View Article and Find Full Text PDFApplication of Targeted RNA-Sequencing in High-Risk B-Cell Acute Lymphoblastic Leukemia (B-ALL): Identifying Fusions, IKZF1 Deletions, and CRLF2 Expression in an Indian Cohort.
Int J Lab Hematol
September 2025
Department of Medical Oncology, Dr BRA IRCH, All India Institute of Medical Sciences (AIIMS), New Delhi, India.
Introduction: B-cell acute lymphoblastic leukemia (B-ALL) is genetically heterogeneous. We assessed the utility of FusionPlex ALL targeted RNA sequencing panel in detecting gene fusions and other genomic lesions in B-ALL.
Methods: The high-risk B-ALL, negative for common recurrent gene fusions (RGF), that is, BCR::ABL1, ETV6::RUNX1, TCF3::PBX1 and KMT2A::AFF1, were analysed with RNA-based targeted sequencing 81-gene-panel FusionPlex ALL (IDT, USA).
Co-existence of Primary Glioma and Lymphoma: An Unusual Case Report.
NMC Case Rep J
August 2025
Department of Pathology, Kurume University School of Medicine, Kurume, Fukuoka, Japan.
Composite or collision tumors in the central nervous system can significantly impact disease progression and metastasis, potentially affecting treatment efficacy. Studying the mechanisms associated with these tumors can provide neuro-oncologists with insights into tumor diversity, progression, and aid in the development of novel treatments. We encountered an 84-year-old female with memory disturbance who presented with tumors consistent with wild-type isocitrate dehydrogenase high-grade glioma and low-grade B-cell lymphoma at the same site.
View Article and Find Full Text PDFPolymerase chain reaction amplification and molecular anatomy of IGH::BCL2 junctions created by ins(14;18)(q32;q21q21).
J Clin Exp Hematop
July 2025
Tenri Institute of Medical Research, Tenri Hospital, Tenri, Nara, Japan.
MYC alterations in multiple myeloma: Genetic insights and prognostic impact.
Neoplasia
August 2025
Hematology Department, University Hospital of Salamanca, IBSAL, Salamanca, Spain; Cancer Research Center-IBMCC (USAL-CSIC), Salamanca, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC, CB16/12/00233), Salamanca, Spain. Electronic address:
Multiple myeloma (MM) is a hematologic malignancy with high genetic complexity. The genetic alterations that drive MM have classically been classified as primary abnormalities, including IGH translocations and hyperdiploidy, and secondary abnormalities, mainly composed of 1q gains, 17p deletions and MYC rearrangements. Dysregulation of the MYC oncogene has been proposed as a key factor in disease progression from monoclonal gammopathy of undetermined significance (MGUS), smoldering MM and overt MM.
View Article and Find Full Text PDF